MARKET

ACTU

ACTU

Actuate Therapeutics Inc
NASDAQ
2.150
-0.120
-5.29%
After Hours: 2.150 0 0.00% 16:10 03/27 EDT
OPEN
2.250
PREV CLOSE
2.270
HIGH
2.250
LOW
2.051
VOLUME
37.31K
TURNOVER
--
52 WEEK HIGH
11.99
52 WEEK LOW
2.051
MARKET CAP
49.97M
P/E (TTM)
-1.8075
1D
5D
1M
3M
1Y
5Y
1D
Actuate Therapeutics FY2025 operating loss narrows 10.59% to $(22.5) million; net loss narrows 18.53% to $(22.2) million
Reuters · 1d ago
Weekly Report: what happened at ACTU last week (0316-0320)?
Weekly Report · 4d ago
Weekly Report: what happened at ACTU last week (0309-0313)?
Weekly Report · 03/16 09:25
Actuate launches research initiative to combine elraglusib, RAS inhibitors
TipRanks · 03/09 12:57
Actuate Therapeutics Launches Strategic Research Initiative To Combine Elraglusib With RAS Inhibitors
Benzinga · 03/09 12:48
ACTUATE THERAPEUTICS INC - INITIAL DATA FROM PROGRAM EXPECTED IN Q2 2026
Reuters · 03/09 12:45
Weekly Report: what happened at ACTU last week (0302-0306)?
Weekly Report · 03/09 09:25
Actuate Therapeutics to Present at the Citizens Life Sciences Conference
Reuters · 03/04 22:00
More
About ACTU
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Webull offers Actuate Therapeutics Inc stock information, including NASDAQ: ACTU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACTU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACTU stock methods without spending real money on the virtual paper trading platform.